Atorvastatin
Product Sizes
10 mg
£ POA
HY-B0589-10MG
50 mg
£ POA
HY-B0589-50MG
100 mg
£ POA
HY-B0589-100MG
500 mg
£ POA
HY-B0589-500MG
200 mg
£ POA
HY-B0589-200MG
10mM/1mL
£ POA
HY-B0589-10MM
About this Product
- SKU:
- HY-B0589
- Application:
- Immunoprecipitation
- CAS Number:
- 134523-00-5
- Extra Details:
- Atorvastatin is an orally active HMG-CoA reductase inhibitor; has the ability to effectively decrease blood lipids. Atorvastatin inhibits human SV-SMC proliferation and invasion with IC50s of 0.39 μM and 2.39 μM; respectively[1][2][3].
- Molecular Weight:
- 558.64
- Purity:
- 99.64
- References:
- [1]Nawrocki, J.W., et al., Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol, 1995. 15(5): p. 678-82.|[2]Santodomingo-Garzón T, et al. Atorvastatin inhibits inflammatory hypernociception. Br J Pharmacol. 2006 Sep;149(1):14-22.|[3]Turner NA, et al. Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion. J Cardiovasc Pharmacol. 2007 Oct;50(4):458-61.|[4]Song XJ, et al. Atorvastatin inhibits myocardial cell apoptosis in a rat model with post-myocardial infarction heart failure by downregulating ER stress response. Int J Med Sci. 2011;8(7):564-72.|[5] Li Y, et al. Inhibition of endoplasmic reticulum stress signaling pathway: A new mechanism of statins to suppress the development of abdominal aortic aneurysm. PLoS One. 2017 Apr 3;12(4):e0174821.|[6]Ming-Bai Hu, et al. Atorvastatin induces autophagy in MDA-MB-231 breast cancer cells. Ultrastruct Pathol. Sep-Oct 2018;42(5):409-415.
- Research Area:
- Metabolic Disease; Inflammation/Immunology; Cancer
- Shipping Conditions:
- Ambient
- Storage Conditions:
- -20[o]C; 3 years; 4[o]C; 2 years (Powder)
- Type:
- Proteins, Peptides, Small Molecules & Other Biomolecules: Small Molecules
- Pathway:
- Autophagy;Metabolic Enzyme/Protease
